论文部分内容阅读
目的分析髓系抗原阳性儿童急性淋巴细胞白血病(ALL)的临床特点及预后关系。方法根据国际白血病欧洲协作组(EGIL)标准将1999—2004年上海交通大学医学院附属上海儿童医学中心收治的33例髓系抗原阳性表达的ALL(My+ALL)分为双表型、双系列型给予正规治疗。对其预后进行观察。结果(1)My+ALL患儿,双表型26例(78.8%,26/33),其中B系ALL伴髓系表达17例(65.4%,17/26),T系ALL伴髓系表达6例(23.1%,6/26),T系B系伴髓系表达3例(11.5%,3/26)。双系列ALL患儿7例(21.2%,7/33)。(2)26例双表型ALL患儿治疗35d,缓解率80.7%。7例双系列型ALL仅1例达缓解(14.3%)。(3)生存状态双表型26例中20例处于缓解状态(76.9%),双系列型7例中仅1例(14.3%)。(4)复发情况双表型6例复发(23.1%,6/26),双系列7例中6例复发(85.7%)。结论髓系抗原阳性表达在儿童ALL时不能作为预后不良的因素,但双系列白血病患儿预后差,复发率高,长期生存机会少。
Objective To analyze the clinical characteristics and prognosis of myeloid antigen-positive childhood acute lymphoblastic leukemia (ALL). Methods According to the International Leukemia European Cooperative Group (EGIL) standard, 33 myeloid antigen positive ALL (My + ALL) patients who were admitted to Shanghai Children’s Medical Center affiliated to Shanghai Jiaotong University School of Medicine from 1999 to 2004 were divided into two groups Formal treatment. The prognosis was observed. Results (1) Twenty-six patients (78.8%, 26/33) with myelodysplastic syndrome in My + ALL patients, including 17 patients with myeloid leukemia (ALL) and 17 Six cases (23.1%, 6/26) had T cell line B with myeloid expression in 3 cases (11.5%, 3/26). Two series of ALL children in 7 cases (21.2%, 7/33). (2) Twenty-six patients with dual-phenotype ALL had a response rate of 80.7% after 35 days of treatment. Only 7 cases of double series of ALL had remission (14.3%). (3) Survival status Twenty cases of double-phenotype were remission (76.9%) in 26 cases and only 1 case (14.3%) of 7 cases of double-series. (4) Recurrence The recurrence occurred in 6 cases of double phenotype (23.1%, 6/26) and in 6 cases of double series (6 cases). Conclusion The positive expression of myeloid antigen in children with ALL can not be used as a prognostic factor, but children with dual leukemia have poor prognosis, high recurrence rate and few long-term survival chances.